Vivus (VVUS +10.2%) soars after Bloomberg Industries claims the prescription insurer payment...

Vivus (VVUS +10.2%) soars after Bloomberg Industries claims the prescription insurer payment rate for the company's Qsymia obesity drug rose 500 bps to 36% in its second week of availability. Vivus had previously suggested the initial coverage rate would be minimal. Also, Vivus has added Express Scripts to Qsymia's home delivery pharmacy network.

From other sites
Comments (5)
  • user418
    , contributor
    Comments (264) | Send Message
    8 Oct 2012, 02:41 PM Reply Like
  • arthurs1
    , contributor
    Comments (396) | Send Message
    Soon will be 50% coverage. Scripts is a behemoth!
    8 Oct 2012, 03:00 PM Reply Like
  • MexCom
    , contributor
    Comments (3077) | Send Message
    VVUS continues to be modest on their projections for marketing progress. But in actuality, they are in full production mode to meet demand. The only problem to develop would be a lack of supply to satisfy the demand. They should then contract out to other manufacturers the billions of pills that will eventually be sold!
    8 Oct 2012, 04:21 PM Reply Like
  • phemale60
    , contributor
    Comments (3034) | Send Message
    Super day!! Now if only my other stocks would act right!! It's always something -- but I'm not complaining!!
    8 Oct 2012, 04:39 PM Reply Like
  • scjs343
    , contributor
    Comment (1) | Send Message
    i am just a plain options trader.I trade occasionally on good tips and recommendation. tks.
    11 Oct 2012, 06:03 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs